California-based INmune decided to leverage its TNF platform and launch a Phase II trial of its selective inhibitor of soluble TNF (sTNF), Quellor, in hospitalised Covid-19 patients. Quellor differs from the existing TNF inhibitors on the market, which are prescribed for inflammatory conditions ranging from rheumatoid arthritis, inflammatory bowel disease and psoriasis, because it only inhibits sTNF, and not transmembrane TNF (tmTNF) as well.